Madrigal

Lexington, United States Founded: 2000 • Age: 26 yrs Listed
Small molecule drugs are developed for cancer and inflammatory diseases.

About Madrigal

Madrigal is a publicly listed company based in Lexington (United States) founded in 2000. Small molecule drugs are developed for cancer and inflammatory diseases. It operates on a HealthTech model. Madrigal has raised $90 million across 3 funding rounds from investors including Caxton Associates, Galleon Group and Military Health. The company has 37 employees. Madrigal has completed 1 acquisition, including Madrigal Pharmaceuticals. Madrigal offers products and services including MASH Treatment. Its focus areas include Biotechnology and Liver Disease Therapeutics. Its legal entity is Madrigal Pharmaceuticals, Inc. Its competitors include Adicet Bio, Orca Bio and Ossium Health; 3 of its 3 listed competitors have raised funding.

Company details

Madrigal Pharmaceuticals, Inc. is engaged in developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a severe liver condition. The companys efforts are directed towards halting or reversing liver scarring and resolving MASH to prevent complications like cirrhosis. Operating within the biopharmaceutical sector, Madrigal has achieved a significant milestone with the first FDA-approved treatment for MASH. Their solutions target high unmet medical needs in liver disease management across the United States and Europe.

  • Headquarters Lexington, United States
  • Employees 37
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website syntapharma.com
  • Social LinkedIn X Facebook
  • Legal Name Madrigal Pharmaceuticals, Inc.
Operational Areas
Key Metrics
  • Annual Revenue
    $180.13 M (USD)
    as on Dec 31, 2024
  • Net Profit
    -$465.89 M (USD)
    -25
    as on Dec 31, 2024
  • EBITDA
    -$497.88 M (USD)
    -31
    as on Dec 31, 2024
  • Total Equity Funding
    $90M (USD)

    in 3 rounds

  • Latest Funding Round
    $999.7K (USD), Grant

    Apr 2011

  • Investors
  • Employee Count
    37
  • Investments & Acquisitions

Products & Services of Madrigal

Madrigal offers a comprehensive portfolio of products and services, including MASH Treatment.

MASH Treatment
Therapeutics

A treatment for metabolic dysfunction-associated steatohepatitis is provided.

Funding Insights of Madrigal

Madrigal has successfully raised a total of $90M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $999.7 thousand completed in April 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $90M
  • Total Rounds 3
  • Last Round Grant β€” $999,699
  • First Round $50M

    (Jan 2004)

  • Investors Count 3

All 3 funding rounds of Madrigal with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2011$999,699Grant––
Oct 2006$40MPrivate Equity Round––
–
Jan 2004$50MSeries C––
Valuation history

3 investors in total: 3 institutional.

Investors in Madrigal

Madrigal has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Caxton Associates, Galleon Group and Military Health.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Diversified asset management is provided by Caxton Associates.
1983caxton.comNew York, United States
galleongrp.com
Administers health care and support for military personnel and operations.
health.milFalls Church, United States
Premium access

Investor details for Madrigal

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Madrigal

288 people are tracked at Madrigal (142 in leadership, 6 in board & advisors, 140 in team); the tracked headcount is 37.

NameRoleGroup
Hetal Panchal
Sr. Director, Data Platform And AnalyticsLeadership
Jason Gay
Regional Business DirectorLeadership
Ron Marchessault
Vice President, Head Of Market AccessLeadership
Kristine Grigoryan
Payroll DirectorLeadership
Zara Gaudioso
Director Human Resources OperationsLeadership
Parth Patel
Executive Director, AI And Data ScienceLeadership
Nancy B.
Director, Commercial Training & DevelopmentLeadership
Christopher Milazzo
Sr. Director, Clinical Practice LiaisonsLeadership
Vanessa MacGregor
Director, Specialty Pharmacy: Market AccessLeadership
Amir Karimzadeh
Senior Director -nash Medical SciencesLeadership
Scott Farris
Sr Director, Health Systems National AccountsLeadership
Ken Liu
Senior Director, National Accounts, US Market AccessLeadership
Brad Giglio
Senior Director National AccountsLeadership
Amber Pace
Northeast Regional Sales DirectorLeadership
John O'Donnell
Vice President, Global Health Economics And Outcomes ResearchLeadership
Carlos Blocker
Regional Sales DirectorLeadership
Lauren van Den Heuvel
Senior Director, Market Access Strategy & OperationsLeadership
Alexandre Felizardo
Executive Director- Market AccessLeadership
Bob O'Rourke
Vice President, Talent AccessLeadership
Kelley Anne Bruni
Director, Key Accounts, Health SystemsLeadership

268 more people are available in the full profile.

Premium access

Complete people profiles for Madrigal

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Madrigal

Madrigal has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Madrigal Pharmaceuticals.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis
madrigalpharma.comConshohocken, United States2011Apr 2016β€’β€’β€’β€’
Premium access

Complete acquisition details for Madrigal

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Madrigal

5 dated milestones of Madrigal across 16 years, from founding to its latest funding, stage changes and deals.

  1. Founded Madrigal is founded.
  2. Funding First funding round of $50.0M.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Grant, of $1,000K.
  5. Acquisition Acquires Madrigal Pharmaceuticals.

Competitors of Madrigal

Madrigal has 3 listed competitors in our database, 3 of them funded. They include Adicet Bio, Orca Bio and Ossium Health.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
adicetbio.com2014Menlo Park, United States$51M86
Immune cell therapies for cancer treatment are developed.
orcabio.com2016Menlo Park, United States$300M66
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
ossiumhealth.com2016San Francisco, United States$125.41M
Ossium Health is focused on bioengineering for improved health.
Premium access

Detailed competitors of Madrigal

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Oncology

3 companies that operate in the same segment as Madrigal (Oncology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Madrigal

PE Week Wire - 7/11/06 - PE Hub
Pehub β€’ 20 years ago
Premium access

Complete news archive for Madrigal

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Madrigal

Madrigal was founded in 2000 and raised its 1st funding round 4 years after it was founded.

Madrigal is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.

Madrigal is a funded company, having raised a total of $90M across 3 funding rounds to date. The company's 1st funding round was a Series C of $50M, raised on Jan 2004.

Madrigal has 37 employees.

Annual revenue of Madrigal is $180.13M as on Dec 31, 2024.

Madrigal Pharmaceuticals, Inc. is engaged in developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a severe liver condition. The companys efforts are directed towards halting or reversing liver scarring and resolving MASH to prevent complications like cirrhosis. Operating within the biopharmaceutical sector, Madrigal has achieved a significant milestone with the first FDA-approved treatment for MASH. Their solutions target high unmet medical needs in liver disease management across the United States and Europe.

Madrigal's top competitors include Orca Bio, Ossium Health and Adicet Bio.

Madrigal offers MASH Treatment.

Madrigal has made 1 acquisition, including Madrigal Pharmaceuticals.

Madrigal has 3 investors. Key investors include Caxton Associates, Galleon Group, and Military Health.

Madrigal operates through Madrigal Pharmaceuticals, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available